Top

Published in:

01-10-2010 | Newborn Screening

Evaluation of the biotinidase activity in hepatic glycogen storage disease patients. Undescribed genetic finding associated with atypical enzymatic behavior: an outlook

Authors: Celia J. Angaroni, Alicia N. Giner-Ayala, Lorena P. Hill, Norberto B. Guelbert, Ana E. Paschini-Capra, Raquel Dodelson de Kremer

Published in: Journal of Inherited Metabolic Disease | Special Issue 2/2010

Abstract

Repeated evaluation of biotinidase (BTD) activity was carried out for a long-term follow-up in patients with hepatic glycogen storage diseases (GSDs). The results indicated inter-intra variability among the GSD-Ia, GSD-III and GSD-IX patients. In addition, a c.1330G>C transversion in the BTD gene, resulting in a p.Asp444His substitution was detected in one allele of a GSD-Ia patient with sustained normal enzyme activity. Thus far, it is necessary to be cautious in the interpretation of the results of BTD activity as a presumptive GSD diagnostic element. It is not known why plasma BTD activity increases in GSDs patients, or the clinical importance of the increment. When viewed from a global perspective, there are some lines of biotin biology that could indicate a relationship between BTD´s behavior and GSDs.

Angaroni CJ, Dodelson de Kremer R, Argaraña CE et al (2004) Glycogen storage disease type Ia in Argentina: two novel glucose-6-phosphatase mutations affecting protein stability. Mol Genet Metab 83:276–279CrossRefPubMed

Angaroni CJ, Labrune P, Petit F et al (2006a) Glycogen storage disease type Ib without neutropenia generated by a novel splice-site mutation in the glucose-6-phosphate translocase gene. Mol Genet Metab 88:96–99CrossRefPubMed

Angaroni CJ, Paschini-Capra A, Giner-Ayala A et al (2006b) Hallazgos inéditos de la biotinidasa plasmática como marcador secundario en la glucogenosis tipo Ia. Posible expansión a otras glucogenosis hepáticas. Medicina (Buenos Aires) 66(suppl II):69–70

Brown DH, Waindle LM, Brown BI (1978) The apparent activity in vivo of the lisosomal pathway of glycogen catabolism in cultured human skin fibroblasts from patients with glycogen storage disease type III. J Biol Chem 253:5005–5011PubMed

Burlina AB, Dermikol M, Muntau A et al (1996) Increased plasma biotinidase activity in patients with glycogen storage disease type Ia: effect of biotin supplementation. J Inherit Metab Dis 19:209–212CrossRefPubMed

Chen YT (2001) Glycogen storage disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease. McGraw Hill, New York, pp 1521–1551

Cole H, Reynolds TR, Lockyer JM et al (1994) Human serum biotinidase cDNA cloning, sequence, and characterization. J Biol Chem 269:6566–6570PubMed

Dakshinamurti K (2005) Biotin-a regulator of gene expression. J Nutr Biochem 16:419–423CrossRefPubMed

Dakshinamurti K, Cheah-Tan C (1968) Liver glucokinase of the biotin deficient rat. Can J Biochem 46:75–80PubMed

Gravel RA, Narang MA (2005) Molecular genetics of biotin metabolism: old vitamin, new science. J Nutr Biochem 16:428–431CrossRefPubMed

Grier RE, Heard GS, Watkins P, Wolf B (1990) Low biotinidase activities in the sera of patients with impaired liver function: evidence that the liver is the source of serum biotinidase. Clin Chim Acta 186:397–400CrossRefPubMed

Hug G, Chuck G, Walling L, Schubert WK (1974) Liver phosphorylase deficiency in glycogenosis type VI: documentation by biochemical analysis of hepatic biopsy specimens. J Lab Clin Med 84:26–35PubMed

Hug G, Chuck G, Tsoras M (1994) Increased serum biotinidase activity in glycogen storage disease type Ia. Pediatr Res 35:203A

Knight HC, Reynolds TR, Meyers GA, Pomponio RJ, Buck GA, Wolf B (1998) Structure of the human biotinidase gene. Mamm Genome 9:327–330CrossRefPubMed

Mayeux R (2004) Biomarkers: potential uses and limitations. NeuroRx 1:182–188CrossRefPubMed

Norrgard KJ, Swango KL, Wolf B (1996) Mutation (D444H) in the biotinidase gene causes approximately 50% loss of enzyme activity and is common in the general population. Am J Hum Genet 59 (suppl):A275

Pabuçcuoğlu A, Aydoğdu S, Baş M (2002) Serum biotinidase activity in children with chronic liver disease and its clinical significance. J Pediatr Gastroenterol Nutr 34:59–62CrossRefPubMed

Paesold-Burda P, Baumgartner MR, Santer R, Bosshard NU, Steinmann B (2007) Elevated serum biotinidase activity in hepatic glycogen storage disorders. A convenient biomarker. J Inherit Metab Dis 30:896–902CrossRefPubMed

Pettit D, Wolf B (1991) Quantitative colorimetric assay of biotinidase activity. In: Hommes FA (ed) Techniques in diagnostic human biochemical genetics: a laboratory manual, 1st edn. Wiley-Liss, New York, pp 561–565

Rodriguez-Melendez R, Zempleni J (2003) Regulation of gene expression by biotin (review). J Nutr Biochem 14:680–690CrossRefPubMed

Saltik IN, Ozen H, Koçak N, Yüce A, Gürakan F (2000) High biotinidase activity in type Ia glycogen storage disease. Am J Gastroenterol 95:2144PubMed

Shin YS (1990) Diagnosis of glycogen storage disease. J Inherit Metab Dis 13:419–434CrossRefPubMed

Wolf B (2001) Disorders of biotin metabolism. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease. McGraw Hill, New York, pp 3935–3962

Wolf B (2005) Biotinidase: its rol in biotinidase deficiency and biotin metabolism. J Nutr Biochem 16:441–445CrossRefPubMed

Wolf B, Freehauf L, Thomas JA, Gordon PL, Greene CL, Ward JC (2003) Markedly elevated serum biotinidase activity may indicate glycogen storage disease type Ia. J Inherit Metab Dis 19:805–809CrossRef

Zempleni J (2005) Uptake, localization, and noncarboxylase roles of biotin. Annu Rev Nutr 25:175–196CrossRefPubMed

Zempleni J, Wijeratne SS, Hassan YI (2009) Biotin. Biofactors 35:36–46CrossRefPubMed

Title: Evaluation of the biotinidase activity in hepatic glycogen storage disease patients. Undescribed genetic finding associated with atypical enzymatic behavior: an outlook
Authors: Celia J. Angaroni
Alicia N. Giner-Ayala
Lorena P. Hill
Norberto B. Guelbert
Ana E. Paschini-Capra
Raquel Dodelson de Kremer
Publication date: 01-10-2010
Publisher: Springer Netherlands
Published in: Journal of Inherited Metabolic Disease / Issue Special Issue 2/2010
Print ISSN: 0141-8955
Electronic ISSN: 1573-2665
DOI: https://doi.org/10.1007/s10545-010-9139-x

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Evaluation of the biotinidase activity in hepatic glycogen storage disease patients. Undescribed genetic finding associated with atypical enzymatic behavior: an outlook

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Special Issue 2/2010

Newborn screening for congenital hypothyroidism: improved assay performance has created an evidence gap

Congenital toxoplasmosis—a report on the Danish neonatal screening programme 1999–2007

The molecular landscape of propionic acidemia and methylmalonic aciduria in Latin America

Initial evaluation of a biochemical cystic fibrosis newborn screening by sequential analysis of immunoreactive trypsinogen and pancreatitis-associated protein (IRT/PAP) as a strategy that does not involve DNA testing in a Northern European population

Cystic fibrosis newborn screening: using experience to optimize the screening algorithm

Postprandial changes of amino acid and acylcarnitine concentrations in dried blood samples

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page